MCRB Seres Therapeutics, Inc.
$5.01▼ -1.76%
Healthcare
Other
After hours
$5.01▲ +0.00%
Sep 11, 7:30 PM ET
Volume 39.6K
Avg Volume (10D) 49.2K
Key Metrics & Fundamentals
Market Cap
$50.32M
P/E Ratio
–
Div Yield
–%
52W Range
4.32 - 29.98
% vs 50 MA
-4.35%
% vs 200 MA
-46.09%
RSI-14
48.8
MACD Histogram
+0.0800
Beta (1Y vs SPY)
1.16
Free Cash Flow
-$22.39M
Gross Rev
$736,000
Gross Profit
$736,000
EBITDA
-$33.99M
COGS
$0
Operating Exp
$16.20M
Operating Income
-$15.47M
EBIT
-$15.47M
Pretax Income
$4.58M
Net Income
$4.58M
EPS (Diluted)
0.47
Price & Volume History
Loading chart…
Recent News
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 8, 2026 10:00 PM
Microbiome Therapeutics Market Report 2026-2035 Featuring Profiles of Ferring Pharmaceuticals, Infant Bacterial Therapeutics, MaaT Pharma, Mikrobiomik, Seres Therapeutics, Vedanta Biosciences
GlobeNewswire · Sep 7, 2026 8:27 AM
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · Sep 1, 2026 11:00 AM
Seres Therapeutics Files $300 Million Mixed Shelf
MT Newswires · Aug 13, 2026 9:25 PM
Seres Therapeutics: Q2 Earnings Snapshot
Associated Press · Aug 5, 2026 11:12 AM
Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs
GlobeNewswire · Aug 5, 2026 11:00 AM
Seres Therapeutics’ SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study
MarketBeat · Jul 10, 2026 6:02 PM
Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday
MT Newswires · Jul 8, 2026 1:13 PM
Seres Therapeutics' Phase 1 Trial of SER-155 Meets Primary Endpoint; Shares Rise Pre-Bell
MT Newswires · Jul 8, 2026 11:55 AM
Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment
GlobeNewswire · Jul 8, 2026 11:00 AM
Financial Overview - Income Statement
Quarterly
Jun 2026
See MCRB's money flow as a full page
Social Sentiment
Avg +0.20 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.